Revised response criteria for malignant lymphoma.

By B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht, S. Horning, B. Coiffier, R. Fisher, A. Hagenbeek, E. Zucca and 10 more. Journal of Clinical Oncology, 2007

4,475 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/04119b92ee3cf452b5d744f549a2230ec9b82bfb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Ronald Boellaard
2. H. Tilly
3. R. Wahl
4. Sally F. Barrington
5. B. Cheson
6. H. Jacene
7. Lawrence H. Schwartz
8. A. Gallamini

Citations in the corpus

• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (2012, methodology): “The best clinical response was determined by both investigators and an IRF (CoreLab Partners, formerly known as RadPharm; Princeton, NJ) according to the Revised Response Criteria for Malignant Lymphoma.12 Response was assessed by CT scans at cycles 2, 4, 7, 10, 13, and 16 and by PET scans at cycles”
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018, neutral): “ORR, % (95% CI) 65 (52-77) 68 (56-78) 73 (63-81) 69 (63-75) Best overall response Complete remission 18 (29) 10 (13) 12 (12) 40 (16) Partial remission 23 (37) 44 (55) 61 (61) 128 (53) Stable disease 15 (24) 17 (21) 15 (15) 47 (19) Progressive disease 7 (11) 6 (8) 10 (10) 23 (9) Unable to determine 0”
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009, background): “This guideline is not intended for use for studies of malignant lymphoma since international guidelines for response assessment in lymphoma are published separately.(14) Finally, many oncologists in their daily clinical practice fol-”
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, methodology): “Response in patients with SLL was evaluated based on the 2007 International Working Group criteria for non-Hodgkin lymphoma.(31)”
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014, methodology): “PET-CT is already widely used for pretreatment assessment, often outside of clinical trials, to assign stage and has already been incorporated into response assessment.(7) Although physical examination remains important, and despite concerns that more sensitive staging can Table 1.”
• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. (2017, neutral): “Vomiting 23 (22) 5 (23) 6 (18) 12 (24) 0 0 0 0 Constipation 22 (21) 6 (27) 7 (21) 9 (18) 2 (2) 1 (5) 1 (3) 0 Headache 19 (18) 2 (9) 7 (21) 10 (20) 0 0 0 0 Anemia 18 (17) 7 (32) 6 (18) 5 (10) 16 (15) 7 (32) 5 (15) 4 (8) Cough 18 (17) 7 (32) 6 (18) 5 (10) 1 (1) 1 (5) 0 0 Neutropenia 18 (17) 4 (18) 8 (”
• Standards for PET Image Acquisition and Quantitative Data Analysis (2009, methodology): “In clinical practice, visual inspection of PET or PET/CT images is the main tool for image interpretation, and for staging or restaging, this method is usually adequate (7,13).”